Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 9/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10122142 | 0.93 | CCR5 (0.41) | GHSRCCR5F2KMT2AATM | |
| SCHEMBL10121985 | 0.92 | GHSR (0.43) | GHSRCCR5F2KMT2AAGTR2 | |
| SCHEMBL1709738 | 0.90 | GHSR (0.46) | GHSRCCR5F2KMT2AAGTR2 | |
| SCHEMBL1709678 | 0.89 | GHSR (0.43) | GHSRCCR5F2KMT2AAGTR2 | |
| SCHEMBL10121971 | 0.89 | GHSR (0.44) | GHSRCCR5KMT2AAGTR2L3MBTL1 | |
| SCHEMBL1709729 | 0.88 | GHSR (0.48) | GHSRCCR5KMT2AMEN1GAA | |
| SCHEMBL1709734 | 0.88 | GHSR (0.49) | GHSRCCR5KMT2AMEN1GAA | |
| SCHEMBL10122225 | 0.88 | GHSR (0.44) | GHSRCCR5KMT2AL3MBTL1MEN1 | |
| SCHEMBL1709691 | 0.88 | GHSR (0.44) | GHSRCCR5KMT2AMEN1 | |
| SCHEMBL10121990 | 0.88 | CCR5 (0.33) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | ELIXIR PHARMACEUTICALS, INC. | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088747-A1 | SULFONAMIDE CONTAINING COMPOUNDS AND USES THEREOF | GHSR, GHRHR, STS | GHSR 1/4885CCR5 4058/4885F2 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.